AndreaBozzo/ceres-open-data-index huggingface dataset:
CMS Program Statistics - Medicare Part D

The CMS Program Statistics - Medicare Part D tables provide use and Part D drug costs by type of Part D plan (stand-alone prescription drug plan and Medicare Advantage prescription drug plan). 

For additional information on enrollment, providers, and Medicare use and payment, visit the CMS Program Statistics page.

 

Below is the list of tables:


	MDCR UTLZN D 1.  Medicare Part D Utilization:  Average Annual Prescription Drug Fills by Type of Plan, Low Income Subsidy (LIS) Eligibility, and Generic Dispensing Rate, Yearly Trend
	MDCR UTLZN D 2.  Medicare Part D Utilization:  Average Annual Gross Drug Costs Per Part D Enrollee, by Type of Plan, Low Income Subsidy (LIS) Eligibility, and Brand/Generic Drug Classification, Yearly Trend
	MDCR UTLZN D 3.  Medicare Part D Utilization:  Average Annual Gross Drug Costs Per Part D Enrollee, by Type of Plan, Low Income Subsidy (LIS) Eligibility, and Brand/Generic Drug Classification, Yearly Trend
	MDCR UTLZN D 4.  Medicare Part D Utilization:  Average Annual Prescription Drug Fills and Average Annual Gross Drug Cost Per Part D Enrollee, by Type of Plan and Demographic Characteristics
	MDCR UTLZN D 5.  Medicare Part D Utilization:  Average Annual Prescription Drug Fills and Average Annual Gross Drug Cost Per Part D Utilizer, by Type of Plan and Demographic Characteristics
	MDCR UTLZN D 6.  Medicare Part D Utilization:  Average Annual Prescription Drug Fills and Average Annual Gross Drug Cost Per Part D Enrollee, by Type of Plan, by Area of Residence
	MDCR UTLZN D 7.  Medicare Part D Utilization:  Average Annual Prescription Drug Fills and Average Annual Gross Drug Cost Per Part D Utilizer, by Type of Plan, by Area of Residence
	MDCR UTLZN D 8.  Medicare Part D Utilization:  Number of Part D Utilizers and Average Annual Prescription Drug Fills by Type of Part D Plan, Low Income Subsidy (LIS) Eligibility, and Part D Coverage Phase, Yearly Trend
	MDCR UTLZN D 9.  Medicare Part D Utilization:  Number of Part D Utilizers and Drug Costs by Type of Part D Plan, Low Income Subsidy (LIS) Eligibility, and Part D Coverage Phase, Yearly Trend
	MDCR UTLZN D 10.  Medicare Part D Utilization:  Number of Part D Utilizers, Average Annual Prescription Drug Events (Fills) and Average Annual Gross Drug Cost Per Part D Utilizer, by Part D Coverage Phase and Demographic Characteristics
	MDCR UTLZN D 11.  Medicare Part D Utilization:  Number of Part D Utilizers, Average Annual Prescription Drug Fills and Average Annual Gross Drug Cost Per Part D Utilizer, by Part D Coverage Phase and Area of Residence
Risk of Infected Blacklegged Tick Encounter: Nymphs (May to Sep): Beginning 2008

Tick-borne diseases, such as Lyme disease, anaplasmosis and babesiosis, are a significant issue in New York (NY), impacting well over 10,000 individuals yearly. The New York State Department of Health (NYSDOH) has a responsibility to perform surveillance to monitor and track different kinds of tick-borne diseases. While most surveillance is done via reportable cases of human illness, tick-borne diseases can also be monitored by collecting ticks from the environment (called active surveillance) and testing them for bacteria, viruses, and parasites known to cause illness in people (collectively called pathogens). Active surveillance allows local county health departments in NY, excluding New York City (NYC), to have a better understanding of the tick populations present in the state, the species composition of the tick population, and the rate at which ticks are infected with different pathogens. The Department started testing ticks in 2002 in limited areas; testing statewide began in 2008. Further information on NYSDOH active tick surveillance  can be found at the URL below and in the Data Methodology section below.
https://www.health.ny.gov/diseases/communicable/lyme/
Patent AT-E39953-T1: [Translated] PLANT FOR MANUFACTURING TEXTILE VELOR NEEDLE FELT WEBS.

Unit for the production of structured textile velour needle-bonded fabric webs from a pre-needle fleece of staple fibers, consisting of a fleece laying apparatus, a pre-needling machine and a velour needling machine, wherein at least the velour needling machine (15) is equipped with a brush belt (21) carrying the fleece to be needled and serving as needle stitch base, said belt being made up of numerous brush plates (24) carrying bristle clusters (25), the outer edges (26) of said plates (24) being of a zig-zag design formed in such a way that the edges (26) of respectively adjacent lying brush plates (24) interlock in such a way that the bristle clusters (25) along the outer edges are spaced at the same distance towards each other as those in the inner area of the brush plates (24), the bristles of the bristle clusters (24) are trimmed on their free ends in a conical or wedge-shaped manner, the holding down plate lies on the fiber fleece web and is pressed down onto it and crown needles (23) are used for the three-dimensional structuring of the pre-needled fiber fleece.
Compound 529531: Methyl ((2-cyano-3,3,3-trifluoro-1-[(2-methoxy-2-oxoethyl)sulfanyl]-1-propenyl)sulfanyl)acetate

Chemical compound data from PubChem database. IUPAC Name: 1-fluorophenanthrene. Molecular Formula: C14H9F. Molecular Weight: 196.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
SHIP Emergency Department Visit Rate Due To Hypertension 2008-2017

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024

Emergency Department Visit Rate Due To Hypertension - This indicator shows the rate of emergency department visits due to hypertension (per 100,000 population). In Maryland, 30% of all deaths were attributed to heart disease and stroke. Heart disease and stroke can be prevented by control of high blood pressure. In Maryland, there were 16,251 emergency department visits for primary diagnosis of hypertension in 2014.
Patent AT-E400226-T1: [Translated] SURGICAL WOUND RETRACTOR

A wound protector and retractor device (80) comprises a sleeve (2), a distal member provided by a distal ring (3) of resilient material and a proximal member provided by a proximal ring (4). The sleeve (2) is led around the ring (3) and is free to move axially relative to the distal ring (3) somewhat in the manner of a pulley. The proximal ring (4) is fixed to the sleeve (2), in this case at the proximal inner end thereof. The resilient distal ring (3) is scrunched up and inserted through the incision (6). The sleeve (2) is then pulled upwardly. On pulling of the sleeve (2) upwardly the outer layer (2b) is pulled up while the inner layer (2a) is drawn around the proximal ring (3). This results in shortening the axial extent between the proximal ring (4) and the distal ring (3), tensioning the sleeve and applying a retraction force to the margins of the incision (6). As the incision is being retracted the margins are also protected by the sleeve. The distal ring (3) is provided with a release mechanism, comprising a cord or ribbon (81), which is coupled at one end (82) to the distal ring (3) and terminates in an outer free end (83) which can be grasped by a user. Pulling the cord or ribbon (81) pulls the distal ring (3), allowing the ring to be released from the inner wall. of the incision (6) to thereby release the device (80).
Compound 525059: Bis(trimethylsilyl)estradiol

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[(13-methyl-3-trimethylsilyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl)oxy]silane. Molecular Formula: C24H40O2Si2. Molecular Weight: 416.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401349-T1: [Translated] MONOCLONAL ANTIBODIES AGAINST MAP PROTEIN AND METHOD FOR USE THEREOF IN THE TREATMENT OR PREVENTION OF INFECTIONS

Monoclonal and polyclonal antibodies to the binding subdomains of the MAP protein, including the Map10 protein, or other immunogenic subregions of the MAP protein, are provided which can be useful in the treatment of and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they serve the double purpose of preventing adherence of the bacteria to host cells and enhancing the killing of the bacteria in an infected host.
The new middle level health workers training in the Amhara regional state of Ethiopia: students' perspective

Background
          Following health sector reform, Ethiopia started training new categories of health workers. This study addresses students' perspectives regarding their training and career plans.
        
        
          Methods
          A cross sectional questionnaire was administered to 145 students in the three schools of the Amhara regional state of Ethiopia.
        
        
          Results
          The majority of students were male (62%) and originally from urban areas (76%). Job search was the most common reason for enrolling in the training for almost half (48%) of the respondents, followed by a desire to help the sick (46%). Once trained, the majority (98%) of graduates preferred to serve in the government sector and in rural health institutions (84%). Females were more willing to work in rural settings [χ2 (df 1)= 7.37; P = 0.007]. The majority (98%) of students felt the training period should be extended. 12% of graduates lacked confidence in their competencies after completing the training. A substantial proportion of the respondents (29%) did not feel the social science courses (Anthropology, Ecology and Psychology) were useful.
        
        
          Conclusions
          This study demonstrates that mid-level health professional students are highly motivated, wish to address the health needs of rural communities, and are interested in professional development. However, students do not feel the training programs are fully addressing their needs. The students found that the duration of the training, the time for theory and practice, the availability of teaching materials, the course contents and their teachers were inadequate. This study suggests that the current training programs have serious inadequacies that need to be addressed.
Compound 529631: 2-Isobutyl-1,3-oxothiolane

Chemical compound data from PubChem database. IUPAC Name: 2-(2-methylpropyl)-1,3-oxathiolane. Molecular Formula: C7H14OS. Molecular Weight: 146.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Community Healthy Marriage Initiative Survey for Six Cities, 2007-2010

The Community Healthy Marriage Initiative (CHMI) evaluation was designed to evaluate community-level impacts of various relationship and marriage education programs. This study compared three sites which received grant funding from the Administration for Children and Families (ACF) (Dallas, Texas; St. Louis, Missouri; and Milwaukee, Wisconsin) with three cities that did not receive grant-funding (Fort Worth, Texas; Kansas City, Missouri; and Cleveland, Ohio) to determine what impacts grant funding has on these types of programs. 

<b>Units of Response: </b>CHMI program participants and non-CHMI program participants

<b>Type of Data: </b>Survey

<b>Tribal Data: </b>No

<b>COVID-19 Data: </b>No

<b>Periodicity: </b>One-time

<b>SORN: </b>https://www.federalregister.gov/documents/2015/04/02/2015-07440/privacy-act-of-1974-system-of-records-notice

<b>Data Use Agreement: </b>https://www.icpsr.umich.edu/rpxlogin

<b>Data Use Agreement Location: </b>https://www.icpsr.umich.edu/web/ICPSR/studies/34719/versions/V3/datadocumentation#

<b>Equity Indicators: </b>Ethnicity;Geographic Areas;Household Income;Household Size;Race;Sex 

<b>Granularity: </b>Individual;Program

<b>Spatial: </b>United States

<b>Geocoding: </b>Zip Code
2015 CMHS Uniform Reporting System (URS) Table for Tennessee

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Tennessee. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Chicago COVID-19 Community Vulnerability Index (CCVI)

The Chicago CCVI identifies communities that have been disproportionately affected by COVID-19 and are vulnerable to barriers to COVID-19 vaccine uptake​. Vulnerability is defined as a combination of sociodemographic factors, epidemiological factors​, occupational factors​, and cumulative COVID-19 burden. 

The 10 components of the index include COVID-19 specific risk factors and outcomes and social factors known to be associated with social vulnerability in the context of emergency preparedness. The CCVI is derived from ranking values of the components by Chicago Community Area, then synthesizing them into a single composite weighted score.  The higher the score, the more vulnerable the geographic area.

ZIP Code CCVI is included to enable comparison with other COVID-19 data available on the Chicago Data Portal. Some elements of the CCVI are not available by ZIP Code. To create ZIP Code CCVI, the proportion of the ZIP Code population contributed by each Community Areas was determined. The apportioned populations were then weighted by the Community Area CCVI score and averaged to determine a ZIP Code CCVI score. 

The COVID-19 Community Vulnerability Index (CCVI) is adapted and modified from a Surgo Ventures collaboration (https://precisionforcovid.org/ccvi) and the CDC Social Vulnerability Index​. ZIP Codes are based on ZIP Code Tabulation Areas (ZCTAs) developed by the U.S. Census Bureau. For full documentation see: https://www.chicago.gov/content/dam/city/sites/covid/reports/012521/Community_Vulnerability_Index_012521.pdf
The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study

Background
          Many randomized trials involve measuring a continuous outcome - such as pain, body weight or blood pressure - at baseline and after treatment. In this paper, I compare four possibilities for how such trials can be analyzed: post-treatment; change between baseline and post-treatment; percentage change between baseline and post-treatment and analysis of covariance (ANCOVA) with baseline score as a covariate. The statistical power of each method was determined for a hypothetical randomized trial under a range of correlations between baseline and post-treatment scores.
        
        
          Results
          ANCOVA has the highest statistical power. Change from baseline has acceptable power when correlation between baseline and post-treatment scores is high;when correlation is low, analyzing only post-treatment scores has reasonable power. Percentage change from baseline has the lowest statistical power and was highly sensitive to changes in variance. Theoretical considerations suggest that percentage change from baseline will also fail to protect from bias in the case of baseline imbalance and will lead to an excess of trials with non-normally distributed outcome data.
        
        
          Conclusions
          Percentage change from baseline should not be used in statistical analysis. Trialists wishing to report this statistic should use another method, such as ANCOVA, and convert the results to a percentage change by using mean baseline scores.
Compound 530003: Silane, [[(3beta,5alpha,17beta)-17-methylandrostane-3,17-diyl]bis(oxy)]bis[trimethyl-

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[(10,13,17-trimethyl-3-trimethylsilyloxy-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl)oxy]silane. Molecular Formula: C26H50O2Si2. Molecular Weight: 450.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Plan Attributes PUF - PY2019

The Plan Attributes PUF (Plan-PUF) is one of the files that make up the Marketplace PUF. The Plan-PUF contains plan-level data on maximum out of pocket payments, deductibles, cost sharing, health savings account (HSA) eligibility, formulary ID, and other plan attributes. These data either originate from the Plans &amp; Benefits template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated). The issuer can also import data created in other templates (e.g., Network IDs from the Network ID template, Service Area IDs from the Service Area template, and Formulary IDs from the Prescription Drug template) to use as allowable values for the applicable fields in the Plans &amp; Benefits template, or enter these values manually.
Compound 525428: 2,2-Bis(methylthio)propane

Chemical compound data from PubChem database. IUPAC Name: 2,2-bis(methylsulfanyl)propane. Molecular Formula: C5H12S2. Molecular Weight: 136.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Estrogen-Astrocyte interactions: Implications for neuroprotection

Background
          Recent work has suggested that the ovarian steroid 17β-estradiol, at physiological concentrations, may exert protective effects in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and acute ischemic stroke. While physiological concentrations of estrogen have consistently been shown to be protective in vivo, direct protection upon purified neurons is controversial, with many investigators unable to show a direct protection in highly purified primary neuronal cultures. These findings suggest that while direct protection may occur in some instances, an alternative or parallel pathway for protection may exist which could involve another cell type in the brain.
        
        
          Presentation of the Hypothesis
          A hypothetical indirect protective mechanism is proposed whereby physiological levels of estrogen stimulate the release of astrocyte-derived neuroprotective factors, which aid in the protection of neurons from cell death. This hypothesis is attractive as it provides a potential mechanism for protection of estrogen receptor (ER)-negative neurons through an astrocyte intermediate. It is envisioned that the indirect pathway could act in concert with the direct pathway to achieve a more widespread global protection of both ER+ and ER- neurons.
        
        
          Testing the hypothesis
          We hypothesize that targeted deletion of estrogen receptors in astrocytes will significantly attenuate the neuroprotective effects of estrogen.
        
        
          Implications of the hypothesis
          If true, the hypothesis would significantly advance our understanding of endocrine-glia-neuron interactions. It may also help explain, at least in part, the reported beneficial effects of estrogen in neurodegenerative disorders. Finally, it also sets the stage for potential extension of the hypothetical mechanism to other important estrogen actions in the brain such as neurotropism, neurosecretion, and synaptic plasticity.
South (S)

This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for the south (e.g., combines Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia) for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
2015 CMHS Uniform Reporting System (URS) Table for Idaho

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Idaho. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
CDC WONDER: Sexually Transmitted Disease (STD) Morbidity

<p>The Sexually Transmitted Disease (STD) Morbidity online databases on CDC WONDER contain case reports reported from the 50 United States and D.C., Puerto Rico, Virgin Islands and Guam.   The online databases report  the number of cases and disease incidence rates by year, state, disease, age, sex of patient, type of STD, and area of report.  Data are produced by the U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, viral Hepatitis, STD and TB Prevention (NCHHSTP).</p>
Special Topic Paper – Child Welfare Waiver Demonstrations and Evidence-Based Programs

This paper explores jurisdictions' efforts to implement and evaluate evidence-based programs (EBPs) as part of a child welfare waiver demonstration from 2012 through the first half of 2019. It addresses the successes and challenges of implementing EBPs; maintaining fidelity to the service models with child welfare populations; and findings related to child and family safety, permanency, and well-being.

Metadata-only record linking to the original dataset. Open original dataset below.
Profiles in Science

Profiles in Science presents the lives and work of innovators in science, medicine, and public health through in-depth research, curation, and digitization of archival collection materials.

This dataset includes full text and metadata describing nearly 30,000 items from Profiles in Science, including digitized correspondence, photographs, laboratory notebooks, diaries, and more that provide insight into the challenges and successes of scientific discovery and the variety of roles, paths, and perspectives involved.

The accompanying README.txt file, downloadable from the Attachments section below, provides a recommended citation and methodological information. The Data Dictionary provides documentation on the variable names, data types, and definitions.

Profiles in Science in its curated form is available at <a href="https://profiles.nlm.nih.gov/">https://profiles.nlm.nih.gov/</a> as well as in <a href="https://collections.nlm.nih.gov">NLM’s Digital Collections</a> for exploration alongside other publicly available digital content, including books, film, prints, photographs, and manuscripts.
Dexmedetomidine

IGALMI is a prescription medication containing dexmedetomidine, available as a sublingual film in 120 mcg and 180 mcg doses. Manufactured by BioXcel Therapeutics, Inc., it acts as a central alpha-2 adrenergic agonist and is used for general anesthesia. This information was generated using AI and is provided for informational and research purposes only.